Cargando…

Correction: L-Rhamnose Is Often an Important Part of Immunodominant Epitope for Pneumococcal Serotype 23F Polysaccharide Antibodies in Human Sera Immunized with PPV23

Detalles Bibliográficos
Autores principales:	Park, Saeyoung, Nahm, Moon H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3891547/ http://dx.doi.org/10.1371/annotation/84458b5b-2bae-4d71-b003-7d584c1bfd8c

Ejemplares similares

L-Rhamnose Is Often an Important Part of Immunodominant Epitope for Pneumococcal Serotype 23F Polysaccharide Antibodies in Human Sera Immunized with PPV23
por: Park, Saeyoung, et al.
Publicado: (2013)

Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against Pneumococcal Disease in the Elderly: Systematic Review and Meta-Analysis
por: Falkenhorst, Gerhard, et al.
Publicado: (2017)

Mechanisms of Immune-Related Long Non-Coding RNAs in Spleens of Mice Vaccinated with 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23)
por: Zhu, Nan, et al.
Publicado: (2023)

1434. Cost-Effectiveness of Sequencial Vaccination With the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Followed by the 23 Valent Polysaccharide Vaccine (PPV23) in The Netherlands
por: Rozenbaum, Mark
Publicado: (2018)

1972. Safety and Immunogenicity of 15-Valent Pneumococcal Conjugate Vaccine (PCV-15) Compared with PCV-13 in Healthy Older Adults Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23)
por: Buchwald, Ulrike, et al.
Publicado: (2018)

Efficacy of PPV23 in Preventing Pneumococcal Pneumonia in Adults at Increased Risk – A Systematic Review and Meta-Analysis
por: Schiffner-Rohe, Julia, et al.
Publicado: (2016)

In vitro growth of pneumococcal isolates representing 23 different serotypes
por: Slotved, Hans-Christian, et al.
Publicado: (2013)

Pneumococcal Disease and the Effectiveness of the PPV23 Vaccine in Adults: A Two-Stage Bayesian Meta-Analysis of Observational and RCT Reports
por: Latifi-Navid, Hamid, et al.
Publicado: (2018)

Effectiveness of 23-valent pneumococcal polysaccharide vaccine on diabetic elderly
por: Kuo, Chia-Sheng, et al.
Publicado: (2016)

Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: A case-control test-negative design study
por: Lawrence, Hannah, et al.
Publicado: (2020)

An adult case of invasive pneumococcal disease due to serotype 12F-specific polysaccharide antibody failure following a 23-valent polysaccharide vaccination
por: Tanaka, Yasuhiro, et al.
Publicado: (2020)

Effect of abatacept on the immunogenicity of 23-valent pneumococcal polysaccharide vaccination (PPSV23) in rheumatoid arthritis patients
por: Migita, Kiyoshi, et al.
Publicado: (2015)

Comparative effectiveness of pneumococcal vaccination with PPV23 and PCV13 in COPD patients over a 5-year follow-up cohort study
por: Ignatova, Galina L., et al.
Publicado: (2021)

Effect of 23-valent pneumococcal polysaccharide vaccine on medical expenses in Japan
por: Satomura, Kazunari, et al.
Publicado: (2014)

Emerging pneumococcal carriage serotypes in a high-risk population receiving universal 7-valent pneumococcal conjugate vaccine and 23-valent polysaccharide vaccine since 2001
por: Leach, Amanda J, et al.
Publicado: (2009)

O-acetylation of typhoid capsular polysaccharide confers polysaccharide rigidity and immunodominance by masking additional epitopes
por: Hitri, Krisztina, et al.
Publicado: (2019)

Cost-effectiveness and budget impact analysis of PPV23 vaccination for the Malaysian Hajj pilgrims
por: Aminuddin, Farhana, et al.
Publicado: (2022)

Discovery of glycerol phosphate modification on streptococcal rhamnose polysaccharides
por: Edgar, Rebecca J., et al.
Publicado: (2019)

The effect of age on the response to the pneumococcal polysaccharide vaccine
por: Lee, Hyunju, et al.
Publicado: (2010)

Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Followed by the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) in Adults with and without Immunosuppressive Therapy
por: Garcia Garrido, Hannah M., et al.
Publicado: (2022)

Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older
por: Vila-Corcoles, Angel, et al.
Publicado: (2010)

Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine against Invasive Pneumococcal Disease in Adults, Japan, 2013–2017
por: Shimbashi, Reiko, et al.
Publicado: (2020)

Pneumococcal Capsular Polysaccharide Structure Predicts Serotype Prevalence
por: Weinberger, Daniel M., et al.
Publicado: (2009)

The structure of the capsular polysaccharide of pneumococcal serotype 11A reveals a novel acetylglycerol that is the structural basis for 11A subtypes.
por: Zartler, Edward R., et al.
Publicado: (2011)

Successful intervention for overwhelming postsplenectomy infection caused by non-vaccine pneumococcal serotype 23A
por: Kojima, Yuichi, et al.
Publicado: (2020)

Effectiveness and practical uses of 23-valent pneumococcal polysaccharide vaccine in healthy and special populations
por: Wang, Yang, et al.
Publicado: (2017)

Creation, characterization, and assignment of opsonic values for a new pneumococcal OPA calibration serum panel (Ewha QC sera panel A) for 13 serotypes
por: Burton, Robert L., et al.
Publicado: (2018)

Impact of Preceding Flu-Like Illness on the Serotype Distribution of Pneumococcal Pneumonia
por: Song, Joon Young, et al.
Publicado: (2014)

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults
por: Shiramoto, Masanari, et al.
Publicado: (2015)

1730. Increasing Vaccination Rates of 23-valent Pneumococcal Polysaccharide Vaccine Among Patients at High-Risk for Invasive Pneumococcal Disease
por: Lyon, Edward, et al.
Publicado: (2023)

Mapping Immunodominant Antibody Epitopes of Abrin
por: Alcalay, Ron, et al.
Publicado: (2020)

Clinical Implications of Pneumococcal Serotypes: Invasive Disease Potential, Clinical Presentations, and Antibiotic Resistance
por: Song, Joon Young, et al.
Publicado: (2013)

Identification of an immunodominant neutralising and protective epitope from measles virus fusion protein using acute post-infection human sera
por: Atabani, S.F., et al.
Publicado: (1997)

The cost-effectiveness of using pneumococcal conjugate vaccine (PCV13) versus pneumococcal polysaccharide vaccine (PPSV23), in South African adults
por: Feldman, Charles, et al.
Publicado: (2020)

Effectiveness, immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine revaccinations in the elderly: a systematic review
por: Remschmidt, Cornelius, et al.
Publicado: (2016)

Divergent humoral responses to 23-valent pneumococcal polysaccharide vaccine in critically-ill burn and neurosurgical patients
por: Mueller, Scott W., et al.
Publicado: (2018)

23-valent polysaccharide vaccine (PPSV23)-targeted serotype-specific identification of Streptococcus pneumoniae using the loop-mediated isothermal amplification (LAMP) method
por: Lee, Jiwon, et al.
Publicado: (2021)

Bacterial glycobiology: rhamnose-containing cell wall polysaccharides in Gram-positive bacteria
por: Mistou, Michel-Yves, et al.
Publicado: (2016)

Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults
por: Schmoele-Thoma, Beate, et al.
Publicado: (2019)

Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
por: Malene B, Mikkelsen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_887b14jke9013rupl0odgtbca6